Biosimilars
At AmerisourceBergen, we believe in the promise of biosimilars to deliver cost savings across healthcare. We also understand the potential hurdles these unique products will face. That's why we offer solutions for increasing access to and confidence in these emerging therapies.
Biosimilars Resource Center
Biosimilar solutions
For providers
Education, solutions & support
Our market-leading GPOs connect physicians and manufacturers for unrivaled purchasing power and education while our provider solutions offer tailored services for all sites of care. Plus, field reimbursement support helps practices navigate payment for these new products.
Download the white paper
The landscape of available biosimilars
In this white paper, we delve into the concept of biosimilars, their distinctions from generics, their impact on reimbursement policies, and the challenges and opportunities they present to healthcare providers, payers, and manufacturers.
FDA Biosimilar Basics
A biosimilar and its original biologic are made from the same types of sources – and have the same treatment risks and benefits. Biosimilars are a type of biologic medication that is safe and effective for treating many illnesses. A biosimilar and its original biologic have the same treatment risks and benefits, and may be available at a lower cost than the original biologics.
"The right conditions exist in the U.S. for biosimilar commercialization success. Competition has proven to bring prices down – look at the generics market over the last 30 years – but now we need to create a supportive system."
- Steve Collis, Chairman, President and CEO, AmerisourceBergen
